{
    "organizations": [],
    "uuid": "58e912b444843777a0bebdfe49d00e5fe87f9fab",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/09/globe-newswire-cesca-therapeutics-to-announce-financial-results-for-the-first-quarter-ended-march-31-2018-and-host-conference-call-on-may.html",
    "ord_in_thread": 0,
    "title": "Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "RANCHO CORDOVA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the first quarter ended March 31, 2018 on Monday, May 14, 2018 after the close of trading. A conference call and webcast will follow at 4:30 p.m. EDT (1:30 p.m. PDT).\nParticipants may access the call by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing “Cesca.” To access a live webcast of the call, please visit: https://services.choruscall.com/links/kool180514.html .\nA replay of the call will be available until June 14, 2018 and can be accessed by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and referencing access code 10119918.\nAbout Cesca Therapeutics Inc.\nCesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing its automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.\nCompany Contact:\nCesca Therapeutics Inc.\nWendy Samford\n916-858-5191\nir@cescatherapeutics.com\nInvestor Contact :\nRx Communications\nPaula Schwartz\n917-322-2216\npschwartz@rxir.com\nSource:Cesca Therapeutics Inc.",
    "published": "2018-05-09T16:30:00.000+03:00",
    "crawled": "2018-05-09T16:23:09.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "rancho",
        "cordova",
        "may",
        "globe",
        "newswire",
        "cesca",
        "therapeutic",
        "cesca",
        "company",
        "nasdaq",
        "kool",
        "market",
        "leader",
        "automated",
        "cell",
        "processing",
        "autologous",
        "therapy",
        "today",
        "announced",
        "company",
        "release",
        "financial",
        "result",
        "first",
        "quarter",
        "ended",
        "march",
        "monday",
        "may",
        "close",
        "trading",
        "conference",
        "call",
        "webcast",
        "follow",
        "edt",
        "pdt",
        "participant",
        "may",
        "access",
        "call",
        "dialing",
        "within",
        "outside",
        "referencing",
        "access",
        "live",
        "webcast",
        "call",
        "please",
        "visit",
        "http",
        "replay",
        "call",
        "available",
        "june",
        "accessed",
        "dialing",
        "within",
        "outside",
        "referencing",
        "access",
        "code",
        "cesca",
        "therapeutic",
        "cesca",
        "therapeutic",
        "develops",
        "commercializes",
        "market",
        "range",
        "automated",
        "technology",
        "therapy",
        "device",
        "division",
        "thermogenesis",
        "provides",
        "full",
        "suite",
        "solution",
        "automated",
        "clinical",
        "biobanking",
        "application",
        "automation",
        "company",
        "developing",
        "automated",
        "platform",
        "streamline",
        "manufacturing",
        "process",
        "emerging",
        "immunotherapy",
        "market",
        "company",
        "contact",
        "cesca",
        "therapeutic",
        "wendy",
        "samford",
        "ir",
        "investor",
        "contact",
        "rx",
        "communication",
        "paula",
        "schwartz",
        "pschwartz",
        "source",
        "cesca",
        "therapeutic",
        "inc"
    ]
}